Clinical Trial Synopsis
|
|
- Ashley Cummings
- 5 years ago
- Views:
Transcription
1 Clinical Trial Synopsis Title of Study: A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects With Chronic Insomnia Protocol Number: Name of Sponsor: Takeda Global Research and Development Brand Name/Active Ingredient Name: ROZEREM /TAK-375 (ramelteon) Page 1 of 5 NCT Number: NCT Publications based on the study: See ClinicalStudyResults.org posting for current publications Study Period: 26 February 2003 through 23 September 2004 Phase of Development: Phase 3 OBJECTIVES Primary: The objective of this study was to assess the long-term safety of regular use of TAK-375. Secondary: None METHODOLOGY Subjects were instructed to take a single oral dose of ramelteon at bedtime and to maintain sleep diaries for 1 year after having completed a 7-day Baseline Lead-in Period during which they completed a sleep diary and a menstrual diary (menstruating women only). Throughout the study, subjects returned to the clinic for safety assessments (including evaluation of adverse events, concomitant medications, sleep diaries, and menstrual diaries [menstruating women only]). At the end of dosing, subjects completed a 3-night Placebo Run-out Period. All study participants received placebo during this period, and all study participants, but not investigators, were blinded to treatment during this run-out period, which was designed to assess the potential for rebound insomnia upon withdrawal of ramelteon. Number of Subjects: Planned: 1000 subjects; Enrolled: 1213 subjects; Analyzed: 1213 subjects Diagnosis and Main Criteria for Inclusion: To qualify for study participation, subjects must have 1) been 18 years of age or older 2) had a body mass index (BMI) between 18 and 34, 3) been willing to sign an informed consent, 4) participated previously in an allowed ramelteon study and had completed all Final Visit procedures from the previous study within 21 days of the Treatment Initiation Visit (or been ramelteon naïve), 5) required long-term treatment for insomnia, 6) had a diagnosis of primary insomnia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revision (DSM-IV-TR ) for at least 3 months and a history of daytime complaint(s) associated with disturbed sleep, 7) a subjective sleep latency (ssl) greater than or equal to 45 minutes and a subjective total sleep time (stst) less than or equal to 6.5 hours per night for at least 3 nights during the week of the Baseline Lead-in Period, based on the subject s sleep diary, 8) had an habitual bedtime between 8:30 PM and 12:00 AM, and 9) not had any sleep schedule changes required by employment (eg, shift worker) within 3 months prior to Day 1 of study medication, or had flown across more than 3 time zones within 7 days prior to Screening.
2 Test Product, Dose and Mode of Administration Ramelteon 8 mg, oral tablet: Ramelteon 16 mg, oral tablet: Placebo 8 mg, oral tablet: Placebo 16 mg, oral tablet: Duration of Treatment: The treatment duration was approximately 1 year. Reference Therapy, Dose and Mode of Administration: Not applicable Page 2 of 5 Lot Number: Z , Z , Z515K011, Z515K031 Z515A031, Z515L011, Z515L021 Z515H011 Z515J011 Criteria for Evaluation: Safety: The primary endpoints of this study were adverse events and changes in vital signs, laboratory tests, electrocardiograms (ECGs), physical examination findings, and menstrual diary results over the course of treatment. Efficacy: The secondary endpoints of this study were subjective sleep assessments (including stst and ssl) collected from subjects diaries over the week preceding each visit. Additional secondary endpoints were the results from clinicians Clinical Global Impression (CGI) scales. Measures of ssl were used to assess rebound insomnia. Statistical Methods: For continuous variables, descriptive statistics included the number of subjects, mean, standard deviation or standard error (as appropriate), minimum, median, and maximum. For categorical data, frequency counts and percentages were presented. Rebound insomnia and safety evaluations were based on observed data only. Summaries of efficacy variables were based on last observation carried forward (LOCF) data. Subject Sets Analyzed: The intent-to-treat (ITT) population was analyzed for safety and efficacy. The ITT population consisted of all subjects who received at least 1 dose of open-label study medication. In practice, analysis for a given variable included only subjects who had a measurement for that variable. Subjects were evaluated according to the actual treatment they received. Summaries of disposition, exposure, compliance, and safety data were presented for subjects who completed 24 (6 months) and 48 weeks (1 year) of dosing. Subjects were considered to be compliant with dosing if they took an average of at least 3 doses per week. In order to be considered compliant subjects in the 24-week group had to have taken at least 72 tablets at the Month 6 Visit and subjects in the 48-week group had to have taken at least 144 tablets at the Month 12 Visit. Data presentations that summarize the ITT Population are synonymous with all subjects; the 24-Week Compliant population is synonymous with the population of subjects who took ramelteon for 6 months; and the 48-Week Compliant population is synonymous with the population of subjects who took ramelteon for 1 year. SUMMARY OF RESULTS Subject Disposition: A total of 1213 subjects enrolled from 123 clinical sites in the United States; 597 completed 6 months of dosing with ramelteon and 472 completed 1 year of dosing with ramelteon. Overall, 473 subjects completed the open-label portion of the trial and 740 discontinued participation in the study. The main reasons subjects discontinued from the study were lack of efficacy (239 subjects, 19.7%), adverse events (148 subjects, 12.2%), and withdrawal of consent (144 subjects, 11.9%). Of the 597 subjects who completed 6 months of dosing with ramelteon, 125 (20.9%), withdrew or were withdrawn from the study before they completed 1 year of dosing with ramelteon. The main reasons given
3 were withdrawal of consent (34 subjects, 5.7%), lack of efficacy (22 subjects, 3.7%), and adverse event (19 subjects, 3.2%), protocol deviations (17 subjects, 2.8%), and lost to follow-up (17 subjects, 2.8%). The mean age of subjects in this trial was 51.6 years; 501 men and 712 women were enrolled. Efficacy Results: Because clinical trials are conducted under a variety of different conditions, the therapeutic effect observed in the clinical trials of a drug cannot be directly compared to the effects found in the clinical trials of other drugs, and may not reflect the therapeutic effects observed in practice. In the same way, therapeutic effects observed in a single clinical trial may not reflect the overall therapeutic effects observed in all clinical trials taken together. The efficacy information acquired from clinical trials does, however, provide a basis for identifying the potential effect a drug may have on subjects participating in the study. ssl (Observed Data): Following regular dosing with ramelteon for both elderly adult and nonelderly adult subjects, ssl improved over the course of the study. At 6 months, the mean ssl was less than 50 minutes (approximately 35 minutes less than Baseline, which was between 85 and 89 minutes); this improvement in ssl was seen as early as at 2 to 3 months. At 1 year, improvements in ssl were sustained and mean ssl was approximately 42 minutes. ssl (LOCF data): Clinically meaningful reductions in ssl from Baseline occurred by month 2 (58.4 minutes for elderly subjects and 60.0 minutes for adult subjects) and month 3 (59.9 minutes for elderly and 58.7 minutes for adult) in both elderly and adult subjects with nightly dosing of ramelteon. At 6 months of nightly dosing, reductions in ssl were sustained and mean ssl were 60.2 minutes for elderly subjects and 58.1 minutes for adult subjects. Following 1 year of nightly dosing, reductions in ssl continued and mean ssl was 59.0 minutes for elderly subjects and 58.3 minutes for adult subjects. stst (Observed Data): The mean observed duration of stst improved over the course of the study. At 6 months, the mean improvement in stst was approximately 1 hour. At 1 year, improvement in stst was sustained and mean stst was approximately 72 to 75 minutes. As demonstrated in mean reduction of ssl, increases in mean stst were seen as early as months 2 and 3. stst (LOCF data): Clinically meaningful increases in stst from Baseline occurred by month 2 for elderly subjects (334.7 minutes) and adult subjects (350.0 minutes) with nightly dosing of ramelteon. At 6 months of nightly dosing with ramelteon for both elderly and adult subjects, improvements in stst were sustained and mean stst was minutes for elderly subjects and for adult subjects. At 1 year, increases in stst from Baseline continued and mean stst was minutes for elderly subjects and minutes for adult subjects. Mean results from CGI indices indicated that: Based on investigators assessment, subjects insomnia condition improved from Baseline at 6 months (global rating of change of condition); this change was sustained at 1 year. There was a moderate and sustained improvement in the severity of illness at 6 months and 1 year. Investigators reported that there was a moderate therapeutic effect of ramelteon at 6 months and 1 year. The results for elderly and adult were similar for all efficacy outcomes. No rebound insomnia occurred in this study, even after 1 year of exposure to ramelteon. Page 3 of 5
4 Safety Results: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of other drugs, and may not reflect the rates observed in practice. In the same way, the rates observed in a single clinical trial may not reflect the overall rates observed in all clinical trials taken together. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. The most common adverse events (ie, occurring in greater than or equal to 5% of the ITT population) reported by all subjects, 24-Week Compliant subjects, and 48-Week Compliant subjects were headache, somnolence, nasopharyngitis, and upper respiratory tract infection. The most common adverse events reported by all subjects were headache (8.7%), somnolence (8.0%), nasopharyngitis (7.9%), upper respiratory tract infection (5.9%) and fatigue (5.1%); by 24-Week Compliant subjects were nasopharyngitis (13.4%), headache (10.9%), upper respiratory tract infection (9.2%), somnolence (7.9%), sinusitis (5.7%), and influenza (5.0%); and by 48-Week Compliant subjects were nasopharyngitis (13.9%), headache (10.9%), upper respiratory tract infection (10.3%), somnolence (8.4%), sinusitis (6.5%), diarrhea (5.3%), and influenza (5.1%). Subjects who took ramelteon for at least 6 months and 1 year had a higher incidences of drug-related (per the investigator) adverse events under the system organ class (SOC) Investigations (10.4% and 9.7%, respectively) than all subjects (6.7%); many adverse events in this category were laboratory results. Subjects who took ramelteon for at least 6 months and 1 year had a lower incidences of events under the Psychiatric Disorders SOC (4.5% and 3.8%, respectively) than all subjects (6.4%). The incidence of abnormal dreams, nightmares and exacerbated insomnia was less in subjects who took ramelteon for at least 6 months and 1 year compared to all subjects. Two subjects died during the study; both subjects were in the ramelteon 16 mg adult group and died as the result of motor vehicle accidents. Neither death was considered by the investigator or the sponsor s medical monitor to be related to study medication. Thirty-eight subjects experienced serious adverse events (SAEs) during the study. Three subjects in the ITT population, 3 subjects in the 24-week Compliant group, and 1 subject in the 48-week Compliant group experienced SAEs that were considered drug-related by the investigator. These events included cerebral vascular accident (8 mg elderly group), syncope (16 mg adult group), and prolactinoma (16 mg adult group). One-hundred forty-seven (12%) subjects experienced treatment-emergent adverse events that led to study drug discontinuation. Three percent of those who completed 6 months of dosing with ramelteon withdrew due to adverse events. Clinical Chemistry For subjects who took ramelteon for 6 months and for 1 year, group mean clinical chemistry values and mean changes from Baseline were unremarkable. Shift changes occurred for a small number of subjects, and almost always, it was less than 2% of subjects for any analyte in either direction. In addition, there did not appear to be any changes in a number of analytes that might reflect systemic diseases or health conditions (eg, increased BUN and creatinine, with alterations in serum protein and albumin might suggest renal disease). The greatest numbers of subjects who had markedly abnormal clinical chemistry values, without regard to whether they had normal values at Baseline occurred for alanine aminotransferase (ALT) (n=8), aspartate aminotransferase (AST) (n=9), gamma glutamyl transferase (GGT) (n=11), blood urea nitrogen (BUN) (n=36), uric acid (n=27), and fasting serum glucose (n=36). The differences between the incidences of subjects with markedly abnormal clinical chemistry results between subjects who took ramelteon for 6 months and for 1 year was small and, when it was different, there were always fewer subjects among those with 1 year of drug exposure compared to those with at least 6 months exposure. Page 4 of 5
5 Hematology Mean hematology values, mean changes from Baseline, and the distribution of the values around the means were contained within the range of normal for all analytes. Mean changes from Baseline at 6 months and at the Final Visit were not clinically important for any value. At Month 6, there were no clinically important differences in the hematology and WBC differential shift results between all subjects and subjects who took ramelteon for 6 months. There also were no clinically relevant changes in these shifts between all subjects at their Final Visit and between all subjects and subjects who took ramelteon for 1 year. The differences between the incidences of subjects with markedly abnormal hematology and WBC results between subjects who took ramelteon for 6 months and for 1 year was small and, as for clinical chemistry results, when it was different there were always fewer subjects among those with 1 year of drug exposure compared to those with at least 6 months exposure. Urinalysis There were no clinically important differences between the results for all subjects and for subjects who completed 6 months and 1 year of dosing with ramelteon. The only shifts in urinalysis values occurred with specific gravity. These findings did not appear to be clinically relevant in the absence of significant clinical findings such as dehydration, for example. The number of subjects who had markedly abnormal urinalysis values and took ramelteon for 1 year was less than for those who took ramelteon for 6 months. Endocrine Tests No clinically important changes in endocrine laboratory parameters were identified. Vital Signs, ECGs, Physical Findings, and Menstrual Diaries Mean vital sign values and changes from Baseline were not considered clinically meaningful at any timepoint or for any analysis performed in this study. There were no major findings as a result of physical examinations. Three subjects had ECGs that became abnormal and clinically important during the trial at 6 months, and 1 subject had an ECG that was abnormal (but not clinically important) that became clinically important during treatment. Four subjects had abnormal and clinically important ECGs that normalized during treatment with ramelteon and 1 that was abnormal and clinically important improved during treatment (ie, no longer clinically important). At the Final Visit, the ECG results were similar; 7 subjects ECGs improved from abnormal and clinically important to normal or abnormal and not clinically important. Five subjects ECGs deteriorated from normal or abnormal (but not clinically important) to abnormal and clinically important. At least 80% of menstruating women reported that their menses were normal at the first, sixth, and twelfth menses during the study. There was a normal distribution in the results for each menses. There did not appear to be any clinically important differences in this distribution for the first, sixth, and twelfth menses compared to the Baseline distribution. Date of Synopsis: 30 September 2008 Page 5 of 5
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Trial Synopsis TL , NCT#
Clinical Trial Synopsis, NCT#00492011 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ability of Ramelteon 1 mg, 4 mg, and 8 mg to Alleviate the Insomnia
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Trial Synopsis TL , NCT#
Clinical Trial Synopsis, NCT#00671398 Title of Study: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Single-Dose Study of TAK-375 in Healthy Adult Volunteers in a Sleep Lab Model
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationBRL /RSD-101RLL/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationSYNOPSIS. Clinical Study Report AI Addendum #1. Open-label Dosing Phase
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: Entecavir SYNOPSIS Clinical
More informationSynopsis. Adalimumab M Clinical Study Report R&D/09/060. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Volume: (For National Authority Use Only) Name of Active Ingredient: Page: Title of Study: A Multi-Center,
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationDrug Review Rozerem (ramelteon)
Drug Review Rozerem (ramelteon) Introduction 1 Ramelteon is a melatonin receptor agonist with affinity for MT 1 and MT 2 and selectivity over the MT 3 receptor. The activity at the MT 1 and MT 2 receptors
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Niaspan Name of Active Ingredient: Page: Niacin extended-release
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationBRL /RSD-101C0F/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/054. (For National Authority Use Only) Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex Sodium Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationSYNOPSIS INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER (FOR NATIONAL AUTHORITY USE ONLY) Volume: Page:
SYNOPSIS Risperdal Risperidone (R064766) Protocol No.: RIS-USA-150 Part 1 INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER AUTHORITY USE ONLY) Title of Study: A Double-Blind, Placebo-Controlled
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More information(+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]pyrimidin-4- one
SYNOPSIS Issue Date: 18 November 2008 Document No.: EDMS-PSDB-9006510:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Ortho-McNeil Janssen Scientific Affairs, L.L.C. Paliperidone
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More information2.0 Synopsis. Adalimumab M Clinical Study Report R&D/04/900. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2. Synopsis Abbott Laboratories Name of Study Drug: Name of Active Ingredient: Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Phase
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationJNJ AAA; paliperidone palmitate Clinical Study Report R SCH-4009
SYNOPSIS Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Asia Pacific Medical Affairs, a Division of Johnson and Johnson Pte Ltd* INVEGA SUSTENNA * The legal entity
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. GENERIC DRUG NAME / COMPOUND NUMBER: Tofacitinib / CP-690,550
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationTitle of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationSYNOPSIS. Clinical Study Report CN138002: Addendum 1. Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abilify Name of Active Ingredient: aripiprazole Individual Study Table Referring to the Dossier (For National Authority Use Only)
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBD
CT Registry ID#5286 Page 1 Summary ID# 5286 Clinical Study Summary: Study B4Z-JE-LYBD An Open Label, Dose-Titration Safety Study of Hydrochloride in Outpatient Japanese Children with Attention-Deficit/Hyperactivity
More informationDrug Class Review on Newer Drugs for Insomnia
Drug Class Review on Newer Drugs for Insomnia Final Report July 00 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of this report is to make available
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationSynopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationJanssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Lyrica / Pregabalin
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationSummary ID# Clinical Study Summary: Study B4Z-JE-LYBC
CT Registry ID# 5285 Page 1 Summary ID# 5285 Clinical Study Summary: Study B4Z-JE-LYBC A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Hydrochloride
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy Number CAIN457C2302 (core study) and CAIN457C2302E1 (extension study)
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Uveitis Approved Indication Investigational Study Number CC2302 (core study) and CC2302E1
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationRestful Sleep or Getting Up to Eat? Suvorexant (Belsomra )
Restful Sleep or Getting Up to Eat? Suvorexant (Belsomra ) Alyssa Penick, PharmD PGY1 Pharmacy Resident UC Health- University of Cincinnati Medical Center Insomnia Most common sleep disorder Defined as
More informationMipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3
(ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,
More informationSupplementary materials
Supplementary materials Table S Adverse events identified by participants diary logs and blood hematologic and biochemical tests (n=2) group (n=) Placebo group (n=) P value for chi-squared test Asthma
More informationIndividual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:
2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSYNOPSIS. Trial No.: RIS-USA-70 Clinical phase: III. JRF, Clinical Research Report RIS-USA-70, 16 October, 1998 N Trial period: Start: 20 Nov 95
SYNOPSIS Trial identification and protocol summary Company: Janssen Research Foundation Finished product: RISPERDAL Active ingredient: Risperidone (R064,766) Title: An open-label, long-term study of risperidone
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-AUS-5 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-AUS-5 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral and psychological symptoms in dementia: a multicenter, double-blind,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPFIZER INC. GENERIC DRUG NAME and/or COMPOUND NUMBER: 5% Spironolactone Cream/ PF
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationProduct: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670
Page 2 of 670 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C Name of Finished Product: Cinacalcet hydrochloride (Sensipar, Mimpara ) Name of ctive Ingredient: cinacalcet (cinacalcet hydrochloride
More informationPFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A3924 4 November 24 Final PFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
More informationCentocor Ortho Biotech Services, LLC
SYNOPSIS Issue Date: 17 June 2009 Name of Sponsor/Company Name of Finished Product PROCRIT Name of Active Ingredient(s) Protocol No.: PR04-15-001 Centocor Ortho Biotech Services, LLC Epoetin alfa Title
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More informationPage: 17 December 2012 (Study M13-692) 22 October 2013 (Study M13-692)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: D2E7 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Studies:
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004
Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST
ACTELION S NEW DUAL OREXIN RECEPTOR ANTAGONIST Investor Webcast July 2016 Copyright The following information contains certain forward-looking statements, relating to the company s business, which can
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More information